Chiesi Farmaceutici S.p.a.

Fabio Rancati

Ian Linney

Andrea Rizzi

Christine Edwards

Chris Knight

Alessandro Accetta

Wolfgang Schmidt

Laura Carzaniga

Gurdip Bhalay

Patrizia Tisselli

Anna Maria Capelli

Arnaud Jean Francois Auguste Cheguillaume

David Edward Clark

Gabriele Amari

Wesley Peter Blackaby

Eleonora Ghidini

Matteo Biagetti

Michael Barnes

Andrea Virdis

Daniele Pala

Andrea Nuzzi

Elizabeth Anne Skidmore

Anna Rencurosi

Wesley Blackaby

Toby Matthew Grover Mullins

Arnaud Jean François Auguste Cheguillaume

Arnaud Jean Fran Ois Auguste Cheguillaume

Stefano Levanto

Nicolò Iotti

Ben Paul Whittaker

Keith Christopher Knight

Barbara Karolina Wolek

Prashant Bhimrao Kapadnis

Roberta Mazzucato

Adele Elisa Pasqua

Anna Karawajczyk

The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Meta tyrosine derivatives as rho-kinase inhibitors

The invention relates to compounds of formula (I) inhibiting Rho Kinase that are oxidazole derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). 

Oxadiazole derivatives as Rho-Kinase Inhibitors

The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Azaindole derivatives as Rho-kinase inhibitors

The invention relates to compounds of formula (I) inhibiting Rho Kinase that are tyrosine analogues derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). 

Tyrosine analogues derivatives as Rho-kinase inhibitors

Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Tyrosine amide derivatives as Rho-Kinase inhibitors

Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).

Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors

Tyrosine amide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Tyrosine amide derivatives as Rho-kinase inhibitors

Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity

Compounds of formula (I), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating diseases of the respiratory tract.

Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.

Growing community of inventors

Parma, Italy

Fabio Rancati